

# Douglas A Stewart

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/253928/publications.pdf>

Version: 2024-02-01

67  
papers

1,103  
citations

566801

15  
h-index

414034

32  
g-index

67  
all docs

67  
docs citations

67  
times ranked

1933  
citing authors

#	ARTICLE	IF	CITATIONS
1	Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. <i>Haematologica</i> , 2022, 107, 690-701.	1.7	43
2	Inferior outcomes with R-CEOP for patients with diffuse large B-cell lymphoma and cardiovascular comorbidities. <i>Leukemia and Lymphoma</i> , 2022, 63, 583-590.	0.6	5
3	Comparison of the Management and Short-Term Outcomes between Patients with Advanced Cancer and Other End-of-Life Conditions Presenting to Two Canadian Emergency Departments. <i>Journal of Palliative Medicine</i> , 2022, , .	0.6	0
4	Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant. <i>Leukemia and Lymphoma</i> , 2022, 63, 2444-2452.	0.6	2
5	NMR-based metabolomic profiling can differentiate follicular lymphoma from benign lymph node tissues and may be predictive of outcome. <i>Scientific Reports</i> , 2022, 12, 8294.	1.6	1
6	Novel synthetic drugs for the treatment of non-Hodgkin lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1417-1427.	0.9	3
7	Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2021, 96, 764-771.	2.0	46
8	Prophylactic high-dose methotrexate in diffuse large B-cell lymphoma, authors' response. <i>American Journal of Hematology</i> , 2021, 96, E339-E341.	2.0	0
9	Excess of deaths for patients with plasma cell proliferative disorders as a result of the COVID-19 pandemic. <i>Leukemia and Lymphoma</i> , 2021, , 1-3.	0.6	0
10	Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience. <i>Blood</i> , 2021, 138, 2525-2525.	0.6	2
11	Favorable Outcomes with Thiotepa/Busulfan-Based Conditioning and Autotransplant for Patients with Aggressive B-Cell Lymphoma and Secondary CNS Involvement. <i>Blood</i> , 2021, 138, 2912-2912.	0.6	1
12	Physician perspectives on delays in cancer diagnosis in Alberta: a qualitative study. <i>CMAJ Open</i> , 2021, 9, E1120-E1127.	1.1	3
13	Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma. <i>Clinical Pharmacokinetics</i> , 2020, 59, 7-23.	1.6	0
14	Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 2492-2496.	0.6	0
15	Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study. <i>Blood</i> , 2020, 136, 16-16.	0.6	2
16	Lack of Effectiveness of Intravenous High-Dose Methotrexate for Prevention of CNS Relapse in Patients with High-Risk DLBCL: A Retrospective Analysis from Alberta, Canada. <i>Blood</i> , 2020, 136, 26-27.	0.6	7
17	Real World Characteristics and Outcomes of Patients with Relapsed and Refractory Diffuse Large B Cell Lymphoma; A Provincial Experience. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
18	Generalizability of Landmark Clinical Trials in Diffuse Large B Cell Lymphoma to Real-World Patients: A Single-Centre Retrospective Cohort Study. <i>Blood</i> , 2020, 136, 17-18.	0.6	0

#	ARTICLE	IF	CITATIONS
19	From symptom to cancer diagnosis: Perspectives of patients and family members in Alberta, Canada. , 2020, 15, e0239374.		0
20	From symptom to cancer diagnosis: Perspectives of patients and family members in Alberta, Canada. , 2020, 15, e0239374.		0
21	From symptom to cancer diagnosis: Perspectives of patients and family members in Alberta, Canada. , 2020, 15, e0239374.		0
22	From symptom to cancer diagnosis: Perspectives of patients and family members in Alberta, Canada. , 2020, 15, e0239374.		0
23	From symptom to cancer diagnosis: Perspectives of patients and family members in Alberta, Canada. , 2020, 15, e0239374.		0
24	From symptom to cancer diagnosis: Perspectives of patients and family members in Alberta, Canada. , 2020, 15, e0239374.		0
25	Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world. <i>Leukemia and Lymphoma</i> , 2019, 60, 133-141.	0.6	16
26	Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2â€“Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes. <i>Breast Cancer: Basic and Clinical Research</i> , 2019, 13, 117822341987942.	0.6	7
27	Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1505-1510.	2.0	10
28	Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model. <i>Blood Advances</i> , 2019, 3, 797-812.	2.5	22
29	Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. <i>Blood</i> , 2019, 133, 919-926.	0.6	89
30	Impact of Cumulative Chemotherapy Dose on Survival With Adjuvant FEC-D Chemotherapy for Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 957-967.	2.3	24
31	Incidence of late onset neutropenia associated with rituximab use in B cell lymphoma patients undergoing autologous stem cell transplantation. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 323-331.	0.5	6
32	The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 829-835.	0.2	2
33	Targeting non-Hodgkin lymphoma with blinatumomab. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1013-1017.	1.4	12
34	Low Counts of B Cells, Natural Killer Cells, Monocytes, Dendritic Cells, Basophils, and Eosinophils are Associated withâ€“Postengraftment Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 37-46.	2.0	22
35	Oseltamivir resistance in an influenza A (H3N2) virus isolated from an immunocompromised patient during the 2014â€“2015 influenza season in Alberta, Canada. <i>Influenza and Other Respiratory Viruses</i> , 2016, 10, 532-535.	1.5	13
36	Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulinâ€“Conditioned Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1654-1663.	2.0	40

#	ARTICLE	IF	CITATIONS
37	Quantifying Benefit of Autologous Transplantation for Relapsed Follicular Lymphoma Patients via Instrumental Variable Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 941-948.	2.0	6
38	Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2016, 57, 28-33.	0.6	14
39	Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 161-170.	1.1	13
40	<i>CD10-positive mantle cell lymphoma</i>: biologically distinct entity or an aberrant immunophenotype? Insight, through gene expression profile in a unique case series. <i>Journal of Clinical Pathology</i> , 2015, 68, 844-848.	1.0	22
41	PARP1 expression in mantle cell lymphoma: the utility of PARP1 immunohistochemistry and its relationship with markers of DNA damage. <i>Hematological Oncology</i> , 2015, 33, 159-165.	0.8	4
42	Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2064-2070.	0.6	22
43	Immune Cell Subset Counts Associated with Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 450-462.	2.0	48
44	Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 1681-1690.	13.9	298
45	Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 1164-1171.	0.8	92
46	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. <i>Blood</i> , 2013, 122, 4277-4277.	0.6	3
47	Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma. <i>Blood</i> , 2013, 122, 4376-4376.	0.6	2
48	Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma. <i>Clinical Cancer Research</i> , 2012, 18, 4962-4972.	3.2	62
49	Prolonged Survival in Secondary CNS Lymphoma Following High Dose Thiotepa/Busulfan-Based Chemotherapy (HDTB) and Autologous Stem Cell Transplantation (ASCT): Single Institution Results From Calgary, Canada. <i>Blood</i> , 2012, 120, 2003-2003.	0.6	3
50	Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score. <i>Leukemia and Lymphoma</i> , 2011, 52, 2124-2129.	0.6	12
51	A Prospective Phase II Study of RICE Re-Induction, Then High-Dose Fludarabine and Busulfan, Followed by Autologous or Allogeneic Blood Stem Cell Transplantation for Indolent B-Cell Lymphoma. ClinicalTrials.gov ID: NCT00144092. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 475-482.	0.2	3
52	Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6. <i>Blood</i> , 2011, 118, 590-590.	0.6	2
53	Gaps in Access to Patient Care for Patients with Rare Hematological Disorders. <i>Blood</i> , 2011, 118, 4752-4752.	0.6	1
54	Interim Restaging PET/CT-Guided High Dose Sequential Induction Therapy with Autologous Stem Cell Transplantation (ASCT) Does Not Improve Outcome for Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL). ClinicalTrials.gov Identifier: NCT00530179. <i>Blood</i> , 2011, 118, 500-500.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Autologous Stem Cell Transplantation Is a Curative Treatment Modality for Relapsed or Refractory Follicular Lymphoma, and Both Recent Rituximab Exposure and Follicular Lymphoma International Prognostic Index (FLIPI) $\geq 1$ Scores Predict Improved Outcome. <i>Blood</i> , 2010, 116, 687-687.	0.6	9
56	pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2009, 50, 1276-1282.	0.6	16
57	FluBup-ATG-TBI for High-Risk or Advanced Adult ALL in Remission: A Retrospective Review of a Mature Cohort.. <i>Blood</i> , 2009, 114, 3384-3384.	0.6	0
58	Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. <i>Blood</i> , 2006, 107, 4623-4627.	0.6	32
59	High Busulfan Exposure Is Associated with Worse Outcome in a Daily IV Busulfan and Fludarabine Transplant Regimen.. <i>Blood</i> , 2006, 108, 313-313.	0.6	2
60	In Vitro and In Vivo Anti Lymphoma Effect of GX15-070 in Mantle Cell Lymphoma.. <i>Blood</i> , 2006, 108, 4756-4756.	0.6	1
61	Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.. <i>Blood</i> , 2006, 108, 3140-3140.	0.6	0
62	Adult Recipients of Matched Related Donor Blood Cell Transplants Given Pretransplant Antithymocyte Globulin Have Less Graft-Versus-Host Disease and Transplant-Related Mortality: Follow-Up of a Matched Pair Analysis.. <i>Blood</i> , 2006, 108, 2865-2865.	0.6	0
63	Dose Intensive Induction Chemotherapy Does Not Decrease Tumor Contamination of Autograft or Improve Survival for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant.. <i>Blood</i> , 2005, 106, 2932-2932.	0.6	0
64	Once Daily IV Busulfan Given with Fludarabine in Allogeneic Stem Cell Transplantation Conditioning: High vs Low Busulfan AUC Does Not Alter Toxicities or Transplant Outcome.. <i>Blood</i> , 2005, 106, 1763-1763.	0.6	0
65	Adult Matched Sibling Blood Cell Transplants (BCT) after Myeloablative Conditioning Incorporating Daily Intravenous (IV) Busulfan (BU) and Low-Dose Antithymocyte Globulin (ATG): Outcomes with Particular Respect to Transplant-Related Mortality (TRM) in 140 Patients.. <i>Blood</i> , 2004, 104, 2313-2313.	0.6	0
66	A Prospective Phase II Comparison of Stem Cell Source Using Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) REA <sup>®</sup> Induction, Then High Dose Fludarabine, Busulfan (FLUBU) and Autologous (ASCT) or Allogeneic (AlloSCT) Hematopoietic Blood Stem Cell Transplantation for Mantle Cell (MCL) and Relapsed Low-Grade B-Cell Non-Hodgkin <sup>™</sup> s Lymphoma (NHL).. <i>Blood</i> , 2004, 104, 915-915.	0.6	0
67	Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. <i>Blood</i> , 2003, 102, 377-387.	0.6	58